Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.49 |
| ▸ | HTR2C | P28335 | 2/20 | 0.49 |
| ▸ | HTR2B | P41595 | 2/20 | 0.49 |
| ▸ | SCN4A | P35499 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 10/20 | 0.46 |
| ▸ | PPARD | Q03181 | 10/20 | 0.46 |
| ▸ | PPARG | P37231 | 9/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10220919 | 1.00 | HTR2A (0.49) | HTR2AHTR2CHTR2BSCN4AEPHX2 | |
| SCHEMBL10219295 | 0.84 | PPARD (0.51) | SCN4AEPHX2PPARAPPARDPPARG | |
| SCHEMBL10219283 | 0.84 | PPARD (0.51) | SCN4AEPHX2PPARAPPARDPPARG | |
| SCHEMBL10219278 | 0.84 | PPARD (0.51) | SCN4AEPHX2PPARAPPARDPPARG | |
| SCHEMBL23744493 | 0.80 | PPARD (0.49) | SCN4AEPHX2PPARAPPARDPPARG | |
| SCHEMBL10219141 | 0.80 | PPARD (0.49) | SCN4AEPHX2PPARAPPARDPPARG | |
| SCHEMBL10220922 | 0.79 | PPARD (0.52) | SCN4AEPHX2PPARAPPARDPPARG | |
| SCHEMBL334293 | 0.79 | PPARD (0.52) | SCN4AEPHX2PPARAPPARDPPARG | |
| SCHEMBL23744747 | 0.79 | PPARA (0.48) | SCN4AEPHX2PPARAPPARDPPARG | |
| SCHEMBL10219145 | 0.79 | PPARA (0.48) | SCN4AEPHX2PPARAPPARDPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-1939189-A1 | DERIVATIVE HAVING PPAR AGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286974-A1 | Derivative having ppar agonistic activity | PPARD, PPARA, PPARG | HTR2A 809/4885HTR2C 947/4885HTR2B 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.